Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Estramustine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.79 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.68 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.68 |
| ▸ | RECQL | P46063 | 2/20 | 0.93 |
| ▸ | BLM | P54132 | 2/20 | 0.93 |
| ▸ | ESR1 | P03372 | 6/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.79 |
| ▸ | INPPL1 | O15357 | 1/20 | 0.79 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.79 |
| ▸ | DRD1 | P21728 | 1/20 | 0.79 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.79 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | ATM | Q13315 | 2/20 | 0.68 |
| ▸ | PGR | P06401 | 2/20 | 0.68 |
| ▸ | AR | P10275 | 2/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estramustine SCHEMBL8342744 | 1.00 | RECQL (0.93) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL22129748 | 1.00 | RECQL (0.93) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL3625800 | 1.00 | RECQL (0.93) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL15710412 | 0.99 | RECQL (0.92) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL13753350 | 0.97 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL7200287 | 0.97 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL6353316 | 0.97 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL29349776 | 0.97 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL29374661 | 0.97 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 | |
| Estramustine SCHEMBL4252 | 0.97 | RECQL (1.00) | RECQLBLMESR1ADORA3INPPL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5973 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083840-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | PREC BIOLOGICS INC (US) | 2026-03-26 | — | — | US | claimed |
| EP-4680284-A2 | BIODEGRADABLE DENDRITIC PARTICLES FOR SUSTAINED DRUG RELEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2026-01-21 | — | — | EP | claimed |
| EP-4644418-A1 | NANOBODY TARGETING BCMA, CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | Hebei Senlang Biotechnology Co. Ltd. (CN) | 2025-11-05 | — | — | EP | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| EP-4608430-A1 | TREATMENT OF PROSTATE CANCER BY PROMOTING PDE4D7 | Koninklijke Philips N.V. (NL) | 2025-09-03 | — | — | EP | claimed |
| US-12292443-B2 | Circulating tumor cell based biomarker composition for diagnosis and prognosis of metastatic prostate cancer | INJE UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2025-05-06 | — | — | US | claimed |
| CN-119907692-A | Isolated targeted delivery system for the treatment of gliomas | 塞尔丽思股份公司 | 2025-04-29 | — | — | CN | claimed |
| US-20250084059-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES INC (US) | 2025-03-13 | — | — | US | claimed |
| CN-119403836-A | Methods for eliminating myeloid-derived suppressor cells using NEO-201 antibodies | 精密生物制品股份有限公司 | 2025-02-07 | — | — | CN | claimed |
| EP-4499710-A1 | METHODS FOR ABLATING MYELOID DERIVED SUPPRESSOR CELLS USING NEO-201 ANTIBODY | Precision Biologics, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| US-5795882-A | Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations | BONE CARE INTERNATIONAL, INC. (US) | 1998-08-18 | — | — | US | claimed |
| WO-1998029123-A1 | METHOD OF TREATING PROSTATIC DISEASES USING ACTIVE VITAMIN D ANALOGUES | BONE CARE INTERNATIONAL, INC. (US) | 1998-07-09 | — | — | WO | claimed |
| WO-1998029105-A2 | METHOD OF TREATING PROSTATIC DISEASES USING DELAYED AND/OR SUSTAINED RELEASE VITAMIN D FORMULATIONS | BONE CARE INTERNATIONAL, INC. (US) | 1998-07-09 | — | — | WO | claimed |
| WO-1998029110-A2 | FORMULATION AND METHOD FOR TREATING NEOPLASMS BY INHALATION | BATTELLE MEMORIAL INSTITUTE (US) | 1998-07-09 | — | — | WO | claimed |
| US-5763429-A | Method of treating prostatic diseases using active vitamin D analogues | BONE CARE INTERNATIONAL, INC. (US) | 1998-06-09 | — | — | US | claimed |
| CN-1170346-A | Process for encapsulation of caplets in capsule and solid dasage forms obtainable by such process | WARNER LAMBERT CO (US) | 1998-01-14 | — | — | CN | claimed |
| EP-0392745-B1 | Immunoconjugates and prodrugs and their use in association for drug delivery | CELLTECH LTD (GB) | 1994-11-02 | — | — | EP | claimed |
| EP-0120907-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | Aston Molecules Limited (GB) | 1984-10-10 | — | — | EP | claimed |
| WO-1984001506-A1 | PHARMACEUTICAL PREPARATIONS FOR USE IN ANTITUMOUR THERAPY | UNIV BIRMINGHAM (GB) | 1984-04-26 | — | — | WO | claimed |
| US-4115414-A | ESTRAMUSTINE PHOSPHATE ALCOHOL COMPLEXES, THEIR PREPARATION, AND THEIR USE AS INTERMEDIATES IN PURIFICATION OF SAID COMPOUND AND SALTS THEREOF | AKTIEBOLAGET LEO (SE) | 1978-09-19 | — | — | US | claimed |